Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book comprehensively covers the mechanisms of action and inhibitor design for HIV-1 integrase. It serves as a resource for scientists facing challenging drug design issues and researchers in antiviral drug discovery. Despite numerous review articles and isolated book chapters dealing with HIV-1 integrase, there has not been a single source for those working to devise anti-AIDS drugs against this promising target. But this book fills that gap and offers a valuable introduction to the field for the interdisciplinary scientists who will need to work together to design drugs that target HIV-1 integrase.

HIV Integrase Inhibitors --- Drug Design. --- HIV Integrase. --- HIV (Viruses) --- Antiviral agents. --- Virus de l'immunodéficience humaine --- Antiviraux --- pharmacology. --- Enzymes --- Inhibitors --- Inhibiteurs --- HIV Integrase --- Drug Design --- Drug Modeling --- Design, Drug --- Designs, Drug --- Drug Designs --- Drug Modelings --- Modeling, Drug --- Modelings, Drug --- HIV Integration Protein --- p31 Integrase Protein, HIV --- p31 Integrase Protein, Human Immunodeficiency Virus --- p31 pol Gene Product, HIV --- p31 pol Gene Product, Human Immunodeficiency Virus --- Integrase, HIV --- Integration Protein, HIV --- Antiviral drugs --- Antivirals --- Anti-infective agents --- Virus diseases --- Virus inhibitors --- AIDS-associated retrovirus --- AIDS virus --- ARV (Viruses) --- HTLV-III (Viruses) --- HTLV-III-LAV (Viruses) --- Human immunodeficiency viruses --- Human T-cell leukemia virus III --- Human T-cell lymphotropic virus III --- Human T-lymphotropic virus III --- IDAV (Viruses) --- Immunodeficiency-associated virus --- LAV (Viruses) --- LAV-HTLV-III (Viruses) --- Lymphadenopathy-associated virus --- T-lymphotrophic virus III, Human --- HTLV (Viruses) --- Virus-induced immunosuppression --- Enzymes. --- Inhibitors. --- pharmacology --- Chemotherapy --- Virus de l'immunodéficience humaine --- Antiviral agents --- Enzymes&delete& --- Computer-Aided Drug Design --- Computerized Drug Design --- Pharmaceutical Design --- Computer Aided Drug Design --- Computer-Aided Drug Designs --- Computerized Drug Designs --- Design, Computer-Aided Drug --- Design, Computerized Drug --- Design, Pharmaceutical --- Designs, Computer-Aided Drug --- Designs, Computerized Drug --- Designs, Pharmaceutical --- Drug Design, Computer-Aided --- Drug Design, Computerized --- Drug Designs, Computer-Aided --- Drug Designs, Computerized --- Pharmaceutical Designs

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This report provides evidence of how much we have achieved and weighs that against our vision for the future: zero new HIV infections, zero discrimination and zero AIDS-related deaths. In these pages you will find scientific analysis, personal insights and the results of extensive national and regional consultations at the front lines of the AIDS response. While perspectives differ, one simple truth emerges: we cannot break the arc of this epidemic - where five people were newly infected for every three starting treatment in 2010 - if we adopt a 'business as usual' approach.

E-books --- HIV Infections. --- Acquired Immunodeficiency Syndrome --- Acquired Immunodeficiency Syndrome. --- AIDS (Disease) --- HIV (Viruses) --- HIV infections --- Public Health --- Health & Biological Sciences --- Communicable Diseases --- HIV (Viruses) infections --- HTLV-III infections --- HTLV-III-LAV infections --- Human T-lymphotropic virus III infections --- Lentivirus infections --- Sexually transmitted diseases --- AIDS-associated retrovirus --- AIDS virus --- ARV (Viruses) --- HTLV-III (Viruses) --- HTLV-III-LAV (Viruses) --- Human immunodeficiency viruses --- Human T-cell leukemia virus III --- Human T-cell lymphotropic virus III --- Human T-lymphotropic virus III --- IDAV (Viruses) --- Immunodeficiency-associated virus --- LAV (Viruses) --- LAV-HTLV-III (Viruses) --- Lymphadenopathy-associated virus --- T-lymphotrophic virus III, Human --- HTLV (Viruses) --- Virus-induced immunosuppression --- Acquired immune deficiency syndrome --- Acquired immunodeficiency syndrome --- Acquired immunological deficiency syndrome --- Immunological deficiency syndromes --- Acquired Immune Deficiency Syndrome --- Acquired Immuno-Deficiency Syndrome --- AIDS --- Immunodeficiency Syndrome, Acquired --- Immunologic Deficiency Syndrome, Acquired --- Acquired Immuno Deficiency Syndrome --- Acquired Immuno-Deficiency Syndromes --- Acquired Immunodeficiency Syndromes --- Immuno-Deficiency Syndrome, Acquired --- Immuno-Deficiency Syndromes, Acquired --- Immunodeficiency Syndromes, Acquired --- Syndrome, Acquired Immuno-Deficiency --- Syndrome, Acquired Immunodeficiency --- Syndromes, Acquired Immuno-Deficiency --- Syndromes, Acquired Immunodeficiency --- CD4-Positive T-Lymphocytes --- HIV-1 --- AIDS Arteritis, Central Nervous System --- HIV Coinfection --- HTLV-III Infections --- HTLV-III-LAV Infections --- T-Lymphotropic Virus Type III Infections, Human --- Coinfection, HIV --- Coinfections, HIV --- HIV Coinfections --- HIV Infection --- HTLV III Infections --- HTLV III LAV Infections --- HTLV-III Infection --- HTLV-III-LAV Infection --- Infection, HIV --- Infection, HTLV-III --- Infection, HTLV-III-LAV --- Infections, HIV --- Infections, HTLV-III --- Infections, HTLV-III-LAV --- T Lymphotropic Virus Type III Infections, Human --- prevention & control. --- History --- Prevention --- Treatment --- Epidemiology